Trials / Completed
CompletedNCT02733094
Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Technical University of Munich · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to explore the efficacy and safety of anti-Interleukin-(IL)17 therapy (secukinumab, administered weekly for 4 weeks followed by four-weekly administration until week 16) for the treatment of pyoderma gangrenosum.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Secukinumab |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2019-09-10
- Completion
- 2019-09-19
- First posted
- 2016-04-11
- Last updated
- 2023-04-12
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02733094. Inclusion in this directory is not an endorsement.